Inflorescence

From vision to reality: Panaxia and Neuraxpharm are the world's first companies to sell medical cannabis extracts for inhalation in Europe

Retrieved on: 
Wednesday, November 3, 2021
Inhalation, Pharmacy, Partnership, TEL, Cannabis, Chronic pain, Tablet, Oil, CNS, Inflorescence, Medication, TASE, Database, LL, Patient, Bachelor of Science, Wax, Smoke, ANSM, Smoking, Marketing, Post-traumatic stress disorder, Chlorophyll, CEO, EU, Growth, Safety, Solution, Publication, Central nervous system, Doctor of Philosophy, Physician, Pharmaceutical industry, Drug

Going forward, our collaboration with Panaxia will allow us to further develop our product offering and provide medical cannabis to promising markets."

Key Points: 
  • Going forward, our collaboration with Panaxia will allow us to further develop our product offering and provide medical cannabis to promising markets."
  • Following the approval, Panaxia and Neuraxpharm became the first and only companies to import and market this type of advanced product in Germany, and in Europe in general.
  • Neuraxpharm will market the products in Germany to physicians certified to prescribe medical cannabis products to patients to treat a wide variety of medical indications.
  • Panaxia views its medical cannabis extracts for inhalation as a strong growth and profitability driver and expects the medical cannabis products for inhalation to capture significant market share in Germany in the coming years, as they have in North America.

Cannassure was granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority

Retrieved on: 
Monday, August 9, 2021
Patent, VP, Breeding, Cannabinoid, TASE, Smoke, Smoking, Method, Patient, JMB, Human, Inhalation, Cannabis, Inflorescence, Pharmaceutical industry, Drug

ASHDOD, Israel, Aug. 9, 2021 /PRNewswire/ -- Cannassure Therapeutics Ltd (TASE: CSURE) ("Cannassure"), an Israel based developer and producer of innovative medical cannabis products, announces today that the company was granted a patent for an oral delivery methodof cannabis and cannabinoids compositionsby the Israel Patents Authority.

Key Points: 
  • ASHDOD, Israel, Aug. 9, 2021 /PRNewswire/ -- Cannassure Therapeutics Ltd (TASE: CSURE) ("Cannassure"), an Israel based developer and producer of innovative medical cannabis products, announces today that the company was granted a patent for an oral delivery methodof cannabis and cannabinoids compositionsby the Israel Patents Authority.
  • Cannassure has been conducting experiments with the new delivery system for the last two years, and following the completion of the development, a patent application was submitted to the Israeli patents authority/ The patent was recently granted to Cannassure.
  • Ran Amir, Cannassure CEO, stated: "The patent approval gives us a competitive advantage in the global market of swallowable cannabis products.
  • Cannassure is engaged in the breeding, cultivating, processing, distribution and R&D of medical cannabis products.